MH
Manhar Hasmatrai Lilaramani
About Manhar Hasmatrai Lilaramani
Data last updated:
Manhar Hasmatrai Lilaramani is a Director at Subhra Pharma Priavate Limited (since 2010). The companies operate in Trading. Subhra Pharma Priavate Limited reported revenue of ₹19.98 Cr (FY 2024). Earlier, Manhar Hasmatrai Lilaramani was a Director at Subhra Life Sciences Private Limited (from 2007).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 19 Aug 2010 | 2010 | ₹19.98 Cr (FY 2024) | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 19 Jun 2007 | 2007 | Strike Off |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Manhar Hasmatrai Lilaramani
| Name | DIN | Company | Designation |
|---|---|---|---|
| Rohini Manhar Lilaramani | 03115118 | Subhra Pharma Priavate Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Manhar Hasmatrai Lilaramani
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Manhar Hasmatrai Lilaramani
Manhar Hasmatrai Lilaramani currently holds 1 directorship: Subhra Pharma Priavate Limited (Director, since 19 Aug 2010, revenue ₹19.98 Cr (FY 2024)).
Manhar Hasmatrai Lilaramani was first appointed on 19 Jun 2007 as Director at Subhra Life Sciences Private Limited. The most recent appointment on record is 19 Aug 2010 at Subhra Pharma Priavate Limited.
Manhar Hasmatrai Lilaramani held 1 earlier board appointment: Subhra Life Sciences Private Limited (Director, from 19 Jun 2007).
The current boards of Manhar Hasmatrai Lilaramani's companies include Rohini Manhar Lilaramani (Subhra Pharma Priavate Limited).